ABCL

AbCellera Biologics, Inc. · NASDAQ

Performance

-3.39%

1W

+5.17%

1M

+4.01%

3M

-5.63%

6M

-50.09%

YTD

-47.51%

1Y

Profile

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Technical Analysis of ABCL 2024-12-20

The stock indicators reflect a neutral sentiment, with the Moving Average Score, Oscillators Score, and Technical Score all at 50, suggesting a balanced market condition without strong bullish or bearish momentum. This indicates that traders may be in a wait-and-see mode, assessing potential catalysts for future price movements.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of ABCL

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.